Lv1
8 积分 2021-09-05 加入
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study
1个月前
已完结
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
1个月前
已完结
Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: Five-year results from the phase III KEYNOTE-564 study
1个月前
已完结
SunRISe-4 perioperative safety and TURBT stratification
1个月前
已完结
AI-predicted spatial transcriptomics unlocks breast cancer biomarkers from pathology
1个月前
已完结
In situ Discovery of Immune Repertoire Reveals Antitumor Immunity and Therapeutic Antibodies
1个月前
已完结
DNMT1-mediated LAMA2 inhibition induces M2 macrophage polarization during prostate cancer progression
2个月前
已完结
GDF15 activates the PI3K/AKT pathway to mediate macrophage M2 polarization to promote prostate cancer resistance to docetaxel
2个月前
已完结
Identification of prostate cancer bone metastasis related genes and potential therapy targets by bioinformatics and in vitro experiments
2个月前
已完结
皖公网安备34019202002308
